GILEAD SCIENCES, INC. GLOBAL RESTRICTED STOCK UNIT ISSUANCE AGREEMENTGlobal Restricted Stock Unit Issuance Agreement • November 5th, 2019 • Gilead Sciences Inc • Biological products, (no disgnostic substances) • Delaware
GLOBAL STOCK OPTION AGREEMENTGlobal Stock Option Agreement • November 5th, 2019 • Gilead Sciences Inc • Biological products, (no disgnostic substances) • Delaware
OPTION, LICENSE AND COLLABORATION AGREEMENT by and between Galapagos NV and Gilead Sciences, Inc. dated as of July 14, 2019Option, License and Collaboration Agreement • November 5th, 2019 • Gilead Sciences Inc • Biological products, (no disgnostic substances) • New York
THIS OPTION, LICENSE AND COLLABORATION AGREEMENT (this “Agreement”) is entered into as of July 14, 2019 (the “Execution Date”) by and between GALAPAGOS NV, a corporation organized under the laws of Belgium and having its principal place of business at Generaal De Wittelaan L11 A3, 2800 Mechelen, Belgium (“Galapagos”), and GILEAD SCIENCES, INC., a Delaware corporation having its principal place of business at 333 Lakeside Drive, Foster City, CA, 94404, USA (“Gilead”). Galapagos and Gilead are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” For purposes of this Agreement, the capitalized terms defined in Appendix A or in other provisions of this Agreement shall have the meanings provided in Appendix A or such other provisions.
Re: Transition Services and General Release AgreementTransition Services and General Release Agreement • November 5th, 2019 • Gilead Sciences Inc • Biological products, (no disgnostic substances) • California
This Transition Services and General Release Agreement (this “Transition Agreement”), which provides for a Supplemental Release (together with the general release herein, the “Releases,” and this Transition Agreement and the Supplemental Release together shall be referred to as the “Agreement”), confirms the terms and conditions of your voluntary resignation of employment with Gilead Sciences, Inc. (the “Company”), as well as the benefits the Company will provide to you in exchange for your consent to be bound by the terms of this Agreement and your execution of the Releases. If you agree to the terms of this Agreement, please sign the last page prior to the expiration date set forth below. Regardless of whether or not you accept this Agreement, you will receive all earned but unpaid compensation in your final paycheck.
Re: Transition Services and General Release AgreementTransition Services and General Release Agreement • November 5th, 2019 • Gilead Sciences Inc • Biological products, (no disgnostic substances) • California
This Transition Services and General Release Agreement (this “Transition Agreement”), which provides for a Supplemental Release (together with the general release herein, the “Releases,” and this Transition Agreement and the Supplemental Release together shall be referred to as the “Agreement”), confirms the terms and conditions of your separation of employment with Gilead Sciences, Inc. (the “Company”), as well as the benefits the Company will provide to you in exchange for your consent to be bound by the terms of this Agreement and your execution of the Releases under and in accordance with the Gilead Sciences, Inc. Retention Program for Executive Officers (the “Retention Program”), which references certain provisions of the Gilead Sciences, Inc. Severance Plan (as amended from time to time, the “Plan”). If you agree to the terms of this Agreement, please sign above your name at the bottom of the last page prior to the expiration date set forth below. Regardless of whether or not you
